Introductory Remarks

T he fi rst GUIDELINES FOR DIS-SO LUT ION TESTIN G OF SOLID ORAL PRODUCTS were published in 198 1
[I] as a joint report of the Section for Official Laboratori es and Medicines Control Services and me Section of Industrial Pharmacists of the F.l.P. These Guide lines were intended as suggestions primarily directed to compendial cOlllmittees, working on the introduction of dissolu tion/ release tests for the respective Pha nnacopoeias.
Duri ng the past decade, there have been mall}1 developments. Biopha rmaceutics has attracted much interest scientifically as well 3S rega rding drug regulatory policies. Dissolution test methodology has been introduced to many Phannacopoeias and a number of regulations and guidelines on bioavailability, bioequi valence and in vitro dissolmion testing have been issued at national and intern ational levels.
These updated Guidelines (second edition) are !:he result of carefu l discussions of the joint 1V0rking group of the two F.l.P. sections and are based on recent developments. Descriptions of test methodology are no longer necessary, because they are already published elsewhere, officially or semi-officially. Differences between the regulations of differem countries and compendias were iden tified and proposals for harmonisation are made.
As far as is reasonable for the purpose of these Guidelines, rechnical terllls and definitions have been adopted from other hannonised recommentions and mainly correspond to USP-renninology. New tenns are "in vitro-in ,~vo comparison," "Verification" and "side batches." "In vitro-in vivo comparison" means any study collecting in vitro-and in vivo-data 011 the sallle set of test specimen to obtain information and understa ndi ng about how in vitro and in vivo performance are related to each other, A significant in vitro-in vh'o correlation can be a result of an in vitro-i n vivo comparison study, hm valuable infornlatioll could also be obtained when no correlation in a strict sense (e.g. USP levels) is achieved. 'I'Verification " is used to define the in vivo data set which provides evidence that a chosen in vitro test method and the proposed limitS are suitable for the drug fonnulation in tenns of biophann3ceutical perfonnance. "Verification " is proposed as a new tenllinus technicus to avoid the extension of "validation" on in vivo investigations. "Side batches') are batches of a given dnlg fonnulation which represent the intended upper and lower dissolution limits. The)' are preferrably to be derived from the defined manufacturing process by setting process parameters within the range of maximum variability expected frolll process validation studies. The term "dissolution" itself is used for all dosage forms,
Concepts of Dissolution Testing
In vitro di ssolution testing serves as an important rool for chanlcrerising the biopharll1:Jccutical quality of a product at different stages in its lifccycle. III early drug dcveloplllcm in vitro dissolution properties arc supportive for choosing between different alternative (annubtion candidates for further development and for evaluation of active ingredientv'drug 5ubst:1I1CCS. In vitro dissolution data are slipporti\,c in the evalua tion and imerpretation of possible risks, especi;:d ly in the c,lse of controlled/modified-release dosage fonns -e.g. as regards dose dumping, food effects on bioavailibility or in teraction with other drugs, which innuence g:lsrrointestinal environmenl;ll conditions. Biophannaceutical aspects are as important for stability concems as they ,Ire for batch release after production, in vitro dissolution being of high relevance in quality control and quality assurance. Last bur nor least, in vitro dissolution data will be of great importance when assessing ch'lIlges in production site, manufacturing process or forIllulation and assist in decisions conceming the need for bioavaibbility studies.
None of these purposes can be fulfilled by an in vitro test system without sufficient reliability. Reliability he re would be defi ned as the system being experimentally sound, yielding precise, accurate, repeatable results and with sufficient knowledge of the in vivo relevance of the dissolution data obt:lined.
telll design was adopted as firs( official method in USP XVIII in 1970, described as rhe rotating basket (apparanlS I, USP).
The rotating basket and the paddle (apparatus 2, USP) devices arc simple, robust and adequately sta ndardised apparatuses which are used all around the world and thus arc supported by the widest experi ence of experilllemaluse. Jt is because of these advantages that rhe paddle and rotating hasket app:lranlses are recommended in various guidelines as first choice for the in vitro dissolution testing of immediate as well as controlled/modified-release preparations.
I lowever, because of the "single container" nature of the paddle/hasket apparatus ex perimental diffi culties may ilrisc in tenns of rhe nced of a change in pH or of any other (p,lrtial) change in the test mcdium during an investigation. Furthermore, difficulties arise for a number of spa ringly soluble dmgs and for some dosage fonns, particuhu·ly aerophilic multiple unit dosage fonns that, tend to float initiall y. Proposals h:lVe been made to increase solubility by addition of .1Il ;lppropri:ltc amount of surfactant. lVith the flow-through cell (a pparatus 4, US P) the specimen is placed in a small colu mn which is continuously flushed with a stream of fluid, si multaneously providing the medium and the mechanical agit<n-ion for dissolution of the drug substa nce. It can be nm as an open as well as a closed system. The open system design especially providcs seve ral advantages in some of the difficult cases mentioned abm'e :md was adopted first by the Deutscher Arl.neimittelcodex (Ge rman Pharmaceutical Codex, DAC) in 198 I.
The now-through apparatus is currentl y monogf<lphed in USP, Ph.ElIr .
• md Ph.J ap. Description of thc system is concordant worldwide. The paddle/basket system is described in USI~ rhe European, the.l'lp'lnese ,Ind many other Pharmacopoeias. Some minor discrepancies are still found in details of the respective monographs. Full Requirements for dissolution testing have been reviewed in the literature 12 -61. Since in vitro dissol ution is a physical test, defined by convention ;md is of a destnlcti\,C nanlrc, proving reliabili ty requires special attcntion. It therefore is within the scope of these products. Il owever, the general concepts Ill,ly be adapt-"' P"ad ""d "I. , ---------------------------ed to in vitro dissolution testing of dmg substa nces/po\\'-Shaft diameter ders, semi-solid oral products, suppositories and, with ~ distinct restrictions, to other non-oral products. Upper chord
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Large Ilumbers of different dissolution ,lpp,lranlses <Ire described in the litenuure, but only some of them withstand critical methodological exam ination.
1\\'0 basic technical principles are ilpplied for in vitro dissolution resting: the "stirred heaker method " and the "flow through procedure," The "stirred beaker method " places the test specimen :lI1d a fixed volume of fluid in a large vessel, and stirring provides mechanical (hydrodynamic) agitation. This closed sys- Guidelines, the latter provides clear evidence that the paddle method should be used' Modification of the apparatus as described in the Ph;mnacopoeias or the harmonisation proposals in T.1bles I and 2 can be intended for automation e.g. of sampling procedure. in such cases, which could potentially have an influence on agitation characteristics [7] , or any other measure, it should be validated on a product-by-product basis that results are equivalent with and without the modification.
II
The pH of the test medium should be set within pH I and 6.8. A higher pH needs to be justified on a case-by-case basis and in general shuuld not exceed pH 8. For low pH in the acidic ra nge Hel should be used (0.1 N I-)el for pl-l I). If, in a certain case, artificial gastric juice without enzymes (pH 1.2) is advantageous, this should be dcmollstT<lted. The use of simulated gastric juice (with pepsin) may be appropri'ltc for gelatine capsules.
In the pH-range of 4.5 to 8.0 USP buffer solutions are recommended, as sUlllmarized in T.1ble 3. A change of pH of dissolution In general, an aqueous medium should be used. It is not recommended to is reasonable, based on the physico-chemical characteristics of drug substance, within the range which a drug or dosage form could experience after oral adm inistration. These following ranges were established based on several conferences and recommendations [e. g. 13 -LSI-The re might be specific products for which no dissolution test can be established without exceeding the recommended ranges of testing conditions. In these cases, it should be clearly demonstrated that dissolution result~ obtained with other, more extreme testing conditions (e.g. pH > 8.0) allow for approp riate biophannaceutical interpretation. For basket/paddle mecllOds the volume should be 500 to 1000 ml. 900 ml had been introduced historically; 1000 ml should be easier to handle in a metric system, th is vol ume being practicable with all equipment commercially available today. 1000 ml therefore should be considered for new drug products or in case of a revision of existing test procedures. This recommendation does not mean that 1000 Illi should be adopted to all existing test procedures and specifications.
Experimental Testing Conditions
Although larger vessels, such as up to 4,000 ml, could be 8 advantageous fo r poorly soluble dmgs, they are not described in compendia, and thus are not as well standardised and therefore should be regarded as modification of a compe ndial method (see section 2.)
DisrollltiollTecim%gieslNOVEMBER 1997 medium during the test or a pH gradient may be appropriate for gastroresistcnt formulations and products for which dissolution testing at one pH-levd or at different pH-levels in parallel does not give biopharmaceutically relevant results.
The use of water as dissolution medium bears the disadvantage that test condition details, such as pH and surface tension, can vary depending on the source of water and may be changed during the dissolution test itself, due to the influence of the dmg product and to the (re)absorption of carbon dioxide frolll air. \Nater therefore is recommended as dissolution medium only when it is proven, that the variations mentioned do not have influence on tl,e dissolution characteristics.
Further additives e.g. enzymes, salts or surfactants, could be considered in specific cases. Their use should be justified as regards nature and concentration of additive [16J. Addition of organic solvents should be avoided.
Agitation typically should be obtained in the basket/paddle apparatus by stirring at 50 to 100 rpm and in general should not exceed 150 rpm. Although maximum discriminatory power should be obtained with lowest stirring rate, in Illilny cases experience with 75 rpm was feltto represent a reliable agitation for paddle equipment [17] .
Regarding media temperature, 37 ± O.5'e should generally be Case-by-case va lidation is also required regarding deaer,ltion since some formulations will be sensitive whereas others are robust in this concern, thus making deaeT<ltion unnecessary. 'fhe deaeration method has to be dearly characterised, since the method chosen can have impact on dissolution profiles [19J. It is noted that the flow rate in the flow-tluough ce ll (open circuit) is particularly sensitive to the presence of air in the medium.
Ph.jap. is currently the only Phannacopoei,l that requi res a specific (very solid) sinker device for all capsule fonnulations. USP recommends a few turns of wire helix when specim en tend to float. EFPIA harmonisation proposal suggests a similar one. Sinkers can significantly influence the in vitro dissolution protlle of a drug 120J. Since they are used especially with fonnulations causing problems during test performance, e.g. flmation, tlley will alter the dissolution profile, so that other recommendations liS] are not applicab le.
The lise of sinkers therefore has to be part of case-by-case dissoluti on validation as well as of in vi tro-Ln vivo comparison shldies. Any strict requirement on use of sinkers or specific sinker types lacks scicntific justification.
Qualification and Validation
Due to the nature of the test method, quality by design is an important qualification aspect for ill vitro dissolution test equi pment. Besides the geometrical and dimensional accuracy and precision as described and commented in section 2 (including Tables I and 2) , any irregularities such as vibration or undesired agitation by mechankal imperfection are to be avoided.
Besides the specification of the apparatus, qualification of dissolution equipment has to consider critical parameters, e.g. temperature of test medium, rotation speed/flow rate, volume, sampling probes and procedures, to be monitored periodically during the periods of use.
Apparatus suitability test is a further important aspect of qualification and va lidation. The use of USP calibrator tablets (disintegrating as well as non-disintegrating) has been controversial for some time. However, it is the only standardised approach and has been helpful to identify system or operator fililurcs. Since some individual drug products might reveal similar or even higher sensitivi ty against technical variance in comparison to USP ca librator tablets, "in-house" standards are judged acceptable as additional, or, if validated, equivalent for ca librator tablets.
The suitability test has to cover each individual apparatus. Paddle lind basket equi pment, as well as 12 mm and 22.6 mill flow-tllrougb cells have to be qualified, unless only paddle or basket, or in the case of flow-through cells only small 0,. large cell is used in one specific piece of equipment. The system su itability test of USP Apparatus must be performed with both a multiparticubue and a monoparticulate standard formulation. A system suitability test for flow-tllrough cells has just been established and will be soon published 1221.
Apparallls suitability tests are recolllmended to be performcd not less than twice per year per equipment and after any equipment change, significant repair or movement. However, a switching between paddle and basket, when the apparatus has been calibrated for both, should not require recalibration.
Additional validation aspects are precise product related operation instructions (e.g. deacration procedure). Dissolution results may be influcnced by the physical behaviour of the specimen stich as floating, adherence to the walls, etc. Thus, critical inspection and observation of test performance during thc test procedure is required. This approach is especially important to explain any "out-lying" results and it dearly limits the extent of automation for a number of drug formulations.
Validation of automated systems, either conceming the sampling and analytica l part or also including media preparation and test performance, has to consider accuracy, precision and avoid com3lllina-£ion by any dilutions, transfers, cleaning or sample or solvent preparation procedures. There should be proof thar there is no interference. This sha ll be evid ence of no significant differences between data obtained with the lllanual dissolution equipment (see section 2) and the automated system, including manipulations sllch as pemlanent sampling probes, additional valves, hollow shafts, etc. Since sensitivity to such modification may be fonnulation related, qualification and validation of automated dissolution equipment and testing has to be established on a case-by-case basis.
Validation of the analytica l procedures applied in dissolution testing, either automa ted or conventiona l, has to comply with "Va lidation of Analytical Procedures" (lCH) and "Y.1Iidation of Compendial Methods" (<1225>, USP). Validation aspects UlUS are accuracy, precision (repeatability, reproducibility), specificity, linearity, range. Special care has to be taken regarding stability of the drug in test medium and sample solutions, since the test procedure often includes exposure to hydrolytic media at 37°C over significant time spans. purposes, the respective dos.lge form h,15 to be thorough1r char<H:-tcri'ied in vitro widl respect to its biopharm:lcclltical performance. Special ancmion has ro be paid to controlled/modified-release preparations, since sufficient information has to be gai ned about hO\\ Illllch the dosage form itse lt~ nlther than variations in test conditions, ~'co n trol" the rate of dntg release.
Formulation Cbamcte>"isation
Therefore, ex rensivc dissolution tests ,lre necessary to l1nderst;lIld the delivery system and to have a rationale for the design of e,g. an in vitro-in vi \,o compariso n study. The in vitro test profile will prefe rahly consist of numerous indi vidual dissolut:ioll test>; under many different rest conditiolls, in volving the pH of test media and agimrion wi thin the ranges given in seerion 3. \ /a riarion of ionic strcngth, surfact:lnts, enzymes or apparatus should be e\',llu,lted, if an influence 0 11 dissolu tion is expected for the individual fonnulation.
For formulation cha racterisa tion, dissolution tests shou ld bc perform ed under th e di ffere nt test conditions until actual di ssolution (e.g. mca n of six specimen) exceeds 80% of labelled amounl. \ \'h en, eve n with test prolonbration, results remain significantly below 80% and solubility is not the limiting parameter, recove ry co ntrol should be performed to prevent misinterpretation of di ssoluLion dar;l.
J\llost in vitro characteristics can be rehlted to ph ysio logic,l l p;u'ameters, such as pi I-profi le of test medi,l (gastric ,mel intestinal pi I), stirring or flow r:lt'e (gastfointestinallllotility, she:l ring forces), :lddition of lipids, enzymes, surfa cta nts (to si mulate the physioiogicil cnvironment). Thus, the information from formulation ch:lracrcrisarion in vitro ca n hc used later ;IS a tool to dcmonstnlte th e rcliabiliry of;lJl in vi[ro-in vivo compari son, based on a distin ct in vi tro model, as \\ell as for interpretation of all those exampl es where no or onl y a poor correlation of in vitro and in vivo data can be achi eved. Ilo\\e\'er, it is obvious thilt ;1 mea ningful in virro*in vivo col11l);}risoll (sec section 6) is [he more probable. the less affected in vitro dissol ution of a given drug formulation is by changes in the environmcntal tcst conditions.
In vitro-in vivo Comparison
An in vitro test system for a given dmg fonnuhttion sen'es as the tool as which it is dcsignated only, if it can disrjnguish hetween "good" and "bad" batches. "Good" here means "of acce pt<lble and reproducibl e hioph;lI'Inaccutical performance in vivo". Thus ill vivo rele\',l1lce of;1ll in vitro test system is sought. The purpose of in vi troin vivo comparison studies in ulis sense is th e scientitic verific1tion of the in vitro tcst system and the respective specificarion limits for a given drug formulation.
Rega rding extended-release dosage fonns the US!' /lSI has catego rised correlative methods, harmonised in a wide international consensus, as correlation b 'el A (I: I re lationship betwee n in vitro and in vivo dissolution, calculated by numeri cal deconvo lution [13, In all other cases at Icast two or three different batches ha\'e to be used, offering differences ill th eir biopharmaccutical propelties, sufficient for correlation pu rposes. Nevertheless, these differences have to he 'effected' by only slllali mod ifications of manufacUJring \'ari-;l bles within the r;1I1ges of the given process. In cases where differences Clllllot be achi eved by th ese va ri ations of the production process, major changes will he required to ohtain samples for in vi tro-i n vivo comparison. Il owever, ;lIlY correlation rccei\tcd for different forrnubtion s bears th e risk of being somewhat arbitrary. A tinal eva luatioll of type and influence of the changes in the lllanUE1C-turing processes requires thorough in \'jtro dissolution tests ('biopharrnaccutical protllc'; see section 5) prior to an administration to human volunteers in a clinical srud y.
Concerning modified-releosl' prodll(f,f th ere is international consensus that levels A to C, \\ ilh ,1 quality ra nking A > B > C, are acceptable for correlation e.g. for speci fications of dissol ution limits. A Ilumber of different reasons (see "11lhle 4) could be responsible for "poor" or no correlation.
Even with highly sophisric:l(ed techniques it is oftcn difficult to ohtain meaningful in vitro-in vivo comparisons, especiall y for biopharmaceutically very similar (hioequivalcnr?) products, such as b:ltches of one drug formulation, representing the upper and th e lower di ssolution limits.
Recellri}" proposals have been Illl1de [301 which in virro-in vi\'o co mparison results scientific:1l1y :1lld formally could suffice as vcrific.ltion of dissolution specification of controlled/modified-release products. In C;lse of :1 signillcant quantitative co rrelation, dissolution limit<; ca n be derived hr interpolation, when batches outside the specified biopharmaccutic:11 range are tested for in vitro-in vivo COI11-parison. Thcll, at Ic,lst three hatches should be tested in vitro and in vivo. A qUi1litativc, i. e. rank-order co rrelation verifies ranges, whcn at least three batches arc tested in vivo flnd ill vitro and the dissolution dflt3 of two of the experimental ly investi g;lted I)fltchcs are concluded bioequiralent and the ir dissolurion chari1cteris-tics are speci/1ed as upper and lower dissolution limits (Fig. I) .
\-\Th ere no correlation IS obtained from an in vitro-in vivo comparison study, an alternative approach (Fig. 2) could consist of demonstrating bioequi\ralencc of the proposed formulation to formulations with dissolution profiles at the upper and lower limits of the specification [13 [ . The number of volunteers to be included in such compara tive bioavailability snldies or in an in vitro-in vivo comparison stlJdy is to be defined on a case-by-case basis but in general should not be less than twelve.
The batch size of a fonnulation for in vitro-in vivo comparison srudies need not be of full production scale. Paramete rs for manufacrure of these batches, especia lly of formulations representing the intended dissolu tion limits, should be defined frolll process validation two-way crossover between an oral solution and a fonnulation representing the (lower) specified dissolution limit. (Fig. J) .
Dissol1ltiol1 Limits
The purpose of specifying dissolution limits is to ensure b;ltchto-batch co nsistency within a range which !,'1Iarantecs acceptable biophal'lll:lceutical perfonmnce in vivo. Limits therefore have to be defined based on experience g;lined during the dmg developmcnt stage ~specia ll y regarding clinical de"elopmelll and/or bioequivalence snldies. In Illost cases deduction of limits requires thorough in vitro-in vivo comparison studies as described in section 6.
For illllllcdiate/conventionalrcie,lse formulations typically one limit is speci~i ed to ensllJ'e thin most of the active ingredient is released within the present time period. Regarding the deduction of limits, diffe rent procedures are recommended, depending on the individual dissolution cha racteristics. However, it is dearl}1 stated, that the following categorisation only concerns the specification verification process. It docs not qualify or disqualify dmg formulations with dissolution properties, characterised by a specified time of > 15 minutes.
In case of velY fast drug releasc, si ngle point dissolution data during cl,e de,'elopment period and a single point specifia1tion, consisting of , 1 pan1llletcr quantitati ng the extent and a parameter to define cl,e time, are judged sufficient. A formulation is in this concern understood as very fast releasing, when at least 80% of the drug substance, corresponding shldies according to the expected maxlInum variability of process pa rameters ("side batches").
to "Q" = 75% (see ~rabl e 5 a in section 8) 
Interpretation, Acceptllnce Criteria
Dissolution test speci6-C' J tions should include the definition of limits, the number of units to be exa min ed and respective acceptance criteria . The procedure of data interpretation should be harmonised inrernationally, the existin g compendial requirements should be uniform .
As pharmacopoeial approaches are still not fully hllrmonised it is recommended to follow Ule acceptance criteria in accordance with US P for immediate! conve nti onal-release products, modifi ed-release (extended-release) products and gastro-resista nt drug release, which is gene"lily understood as ~80%. The dissolution run in quali ty comrol therefo re should be extended for the tillle interval until ;It least 80% of drug substa nce is disso lved. Shoner test imerv.lls can be ,lcceptable in special cases but require justification on the basis of (delayed-release) products Crable 5). The approach with a maximum of three stages and individual units tested for deviation from stated ranges corresponds well to requirements for coment uni fomlity. Although there is preference ill common pnlctice in pharmaceutical industries {Q decide upon batch release not later than stage 2, the three Disso/Illio7l7ecim%giesINOVEMBER 1997 step approach is the best solution for formal specifications, especially when referring to end-of-shelf life specification. Reference to labelled content docs not apply for products with intentional di fferent content at tim e of manufacrurillg, Stich as in cases of stability overage.
Special A pplications
A spcci~i c value of dissolution testing is recognized in its applicati ons in scale-up and manufacturing changes for immediate/con ventional-release and lJlodi~ed -rel e<lse oral products. The AAPS/FDA/USP Seale-up workshops 134, 151 recommend cCitain 
J O. COllclusiolls
In ma ny interna tiona l discussions, Ill'lill ly over the years 1988 to 1993, consensus was reached on some essential aspects, to which th ese Guidelin es refer. On th e oth er hand, man y aspects have either not ye t been sufficientl y explored or have not been harlllonised. In these cases, e.g. morc precise specifications of dissolution media and proposals for in vitro-in vivo comparison approaches and verification of specifi cations for illlll1edi<lte/conventional -releasc, delayed-release and modified-release preparations, th e revi sed Guidelines will provide contributions for reasonable standardization, whil e acknowledging tha t for a numher of dnlgs e.g. wi th special physico-chemical or ponenrs and composition, site of manufacturing, th e sc,ll e of ll1 ,lI1ufaculring, and process and equipment Table G Depending on the level of change, different Icvels of dissolu tion testing are recommended to assure continuing product qual ity and performan ce characteristi cs. Respectively, the documentation needed to assure the product performance vari es, depending on theraSodium lauryl sulfate Sodium Chloride Distilled Water 2.5 G 2.0 G qs. 1000 ml peutic ran ge, solubility and pemleabili ty fa ctors of the drug. For changes greater than th e acceptable valu es in the scale-up workshop report, addi tional dissolution profile determina tions in se\'eralmcdia are recommended for immediate-release products. For major changes, tha t are likely to ha ve a significa nt impact on formulati on quality and performance, an in vivo bioequi v,llence study is recommended in addition to extensive disso lution profile resting. For manufacturin g site change, scal e-up, equipment changes <lnd minor process changes dissolution testing is deemed sufficient to assure product quality and performan ce.
[n vitro dissolution tests have al so been used to try to simulate food-effects on bioavailability. So far, these different attempts 117 -41] ha ve had extremely limited success in prediction 1441 . Assuming tha t gastro-in testinal transit times are sif,rnificanrly contributing to potential food-effects on bioavailability, the value of an in vitro model for food-effects will be limited to an evaluation whether direct drugfood-interaction could be of relevance for th e observed changes in bioavailability in the in vi vo srudy. Test media that may refl ect gastric conditions (fasted) and intestinal conditions (fastedlfed) and thus may give additional infonnation for research and developm ent purpose are summarised in especially applicable fo r industry, dmg authorities and contro l laboratories but al so for uni ve rsiti es, hospitals, phannilcies or others, wh en involved in (bio)pharmilceutical qllaliry eva luation.
til general these Guidelines should be understood as recommendations based on scientific knowledge and experience. They should be help hll in the dialob~le with drug regula tory authorities. However they arc not intended to represent any offI cial requirements in this neld.
